{"organizations": [], "uuid": "cbe36d4460924107d9cadd900899c785e02e20f1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180409.html", "section_title": "Archive News &amp; Video for Monday, 09 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pangaea-oncology-signs-strategic-d/brief-pangaea-oncology-signs-strategic-deal-in-oncological-diagnosis-with-qiagen-idUSFWN1RM06L", "country": "US", "domain_rank": 408, "title": "BRIEF-Pangaea Oncology Signs Strategic Deal In Oncological Diagnosis With Qiagen", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.062, "site_type": "news", "published": "2018-04-09T15:19:00.000+03:00", "replies_count": 0, "uuid": "cbe36d4460924107d9cadd900899c785e02e20f1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pangaea-oncology-signs-strategic-d/brief-pangaea-oncology-signs-strategic-deal-in-oncological-diagnosis-with-qiagen-idUSFWN1RM06L", "ord_in_thread": 0, "title": "BRIEF-Pangaea Oncology Signs Strategic Deal In Oncological Diagnosis With Qiagen", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "pangaea oncology sa", "sentiment": "negative"}, {"name": "qiagen", "sentiment": "negative"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 9 (Reuters) - Pangaea Oncology SA:\n* SAYS SIGNS STRATEGIC AGREEMENT IN ONCOLOGICAL DIAGNOSIS WITH GERMAN DIAGNOSTIC MULTINATIONAL QIAGEN\n* SAYS DEAL HAS INITIAL DURATION OF THREE YEARS, EXTENDABLE ANNUALLY BY MUTUAL AGREEMENT\n* AS FIRST STEP CO TO PERFORM QIAGEN TECHNOLOGY VALIDATION TASKS FOR DIAGNOSIS OF VARIOUS TUMOR TYPES\n* THIS CONTRACT IS FOR AN AMOUNT OF 149,000 EUROS OVER A PERIOD OF SIX MONTHS Source text: bit.ly/2qiR1gq Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://bit.ly/2qiR1gq", "https://www.youtube.com/user/ReutersVideo", "https://twitter.com/reuters", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-09T15:19:00.000+03:00", "crawled": "2018-04-10T12:47:21.009+03:00", "highlightTitle": ""}